APRE

Aprea Therapeutics, Inc.

• Benzinga·19h ago

  12 Health Care Stocks Moving In Thursday's After-Market Session

• Benzinga·09/22 12:33

  Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer Therapeutics

• NASDAQ·08/28 15:55

  Aprea Expands Patent Portfolio For Precision Oncology Programs

• TipRanks·08/28 13:37

  Aprea Therapeutics Expands Global IP for Precision Oncology

• TipRanks·08/28 12:20

  Aprea Therapeutics provides update on existing patent portfolio

• Benzinga·08/28 12:17

  Aprea Therapeutics Expands Current Patent Portfolio

• Benzinga·08/27 17:06

  12 Health Care Stocks Moving In Thursday's Intraday Session

• Benzinga·08/24 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• TipRanks·08/14 14:10

  Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), Nektar Therapeutics (NKTR) and Aprea Therapeutics (APRE)

• Dow Jones·08/13 13:06

  Aprea Therapeutics Is Maintained at Outperform by Wedbush

• Dow Jones·08/13 13:06

  Aprea Therapeutics Price Target Cut to $3.00/Share From $6.00 by Wedbush

• Benzinga·08/13 12:55

  Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

• TipRanks·08/13 11:50

  Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)

• NASDAQ·08/12 17:15

  Aprea Advances APR-1051; Phase 1 Enrollment Accelerates

• TipRanks·08/12 12:58

  Aprea Therapeutics advances APR-1051 oncology pipeline progress